Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 2/2010

01.04.2010 | Case Report

Severe ifosfamide-induced neurotoxicity: a case report

verfasst von: Sara Ramos Linares, Joaquín Breña Atienza, Matilde Cháfer Rudilla, Pablo Ríos Rull, Ana Cabello Rodríguez, Javier Merino Alonso

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction Ifosfamide is an alkylating agent used in the treatment of several neoplasias. Ifosfamide metabolites accumulation can produce neurotoxicity, which sometimes manifests as a severe clinical picture. Case description We describe the case of a male with a mixed cellularity subtype classical Hodgkin’s lymphoma, treated with ifosfamide after other chemotherapy drugs failure. After the first Ifosfamide cycle, the patient showed severe neurological toxicity that resolved 3 weeks later with supportive therapy. Discussion Among the risk factors described in the literature, our patient had previously received cysplatin chemotherapy, had low albumin serum levels, and had received ifosfamide as a rapid intravenous infusion. The management of the neurotoxicity is symptomatic although some drugs, like methylene blue and albumin, have also been used. Conclusion This case highlights that clinicians should be aware of the possibility of severe neurological toxicity after the administration of ifosfamide and may control the risk factors associated.
Literatur
1.
Zurück zum Zitat Klatersky J. Side effects of ifosfamide. Oncology. 2003;65(suppl 2):7–10.CrossRef Klatersky J. Side effects of ifosfamide. Oncology. 2003;65(suppl 2):7–10.CrossRef
2.
Zurück zum Zitat Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anti-Cancer Drugs. 2004;15:347–50.CrossRefPubMed Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anti-Cancer Drugs. 2004;15:347–50.CrossRefPubMed
3.
Zurück zum Zitat Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol. 2007;19(2):108–14.CrossRef Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol. 2007;19(2):108–14.CrossRef
4.
Zurück zum Zitat Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, vinorelbine: a new induction regimen for refractory, relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35–41.CrossRefPubMed Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, vinorelbine: a new induction regimen for refractory, relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35–41.CrossRefPubMed
6.
7.
Zurück zum Zitat Patel PN. Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother. 2006;40:299–303.CrossRefPubMed Patel PN. Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother. 2006;40:299–303.CrossRefPubMed
8.
Zurück zum Zitat David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005;28(3):277–80.CrossRefPubMed David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005;28(3):277–80.CrossRefPubMed
9.
Zurück zum Zitat Hamadani M, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Pract. 2006;2(40):299–303. Hamadani M, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Pract. 2006;2(40):299–303.
10.
Zurück zum Zitat Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82:291–4.CrossRefPubMed Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82:291–4.CrossRefPubMed
Metadaten
Titel
Severe ifosfamide-induced neurotoxicity: a case report
verfasst von
Sara Ramos Linares
Joaquín Breña Atienza
Matilde Cháfer Rudilla
Pablo Ríos Rull
Ana Cabello Rodríguez
Javier Merino Alonso
Publikationsdatum
01.04.2010
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 2/2010
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-009-9354-4

Weitere Artikel der Ausgabe 2/2010

International Journal of Clinical Pharmacy 2/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.